{"id":43176,"date":"2025-10-13T17:22:19","date_gmt":"2025-10-13T09:22:19","guid":{"rendered":"https:\/\/flcube.com\/?p=43176"},"modified":"2025-10-13T17:22:20","modified_gmt":"2025-10-13T09:22:20","slug":"everest-medicines-receives-nmpa-approval-for-universal-oncology-vaccine-evm14","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43176","title":{"rendered":"Everest Medicines Receives NMPA Approval for Universal Oncology Vaccine EVM14"},"content":{"rendered":"\n<p><strong>Everest Medicines Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1952:HKG\">HKG: 1952<\/a>) announced today that the National Medical Products Administration (NMPA) has approved the <strong>Investigational New Drug (IND)<\/strong> application for its universal, off\u2011the\u2011shelf therapeutic oncology vaccine <strong>EVM14 for Injection<\/strong>. The IND clearance follows the U.S. Food and Drug Administration (FDA) approval of the same clinical trial in March\u202f2025, positioning EVM14 for accelerated global development.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-product-profile\">Product Profile<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>EVM14<\/strong> \u2013 a next\u2011generation, mRNA\u2011based therapeutic vaccine developed on Everest\u2019s proprietary platform.<\/li>\n\n\n\n<li><strong>Universal Design<\/strong> \u2013 targets <strong>five tumor\u2011associated antigens (TAAs)<\/strong>, enabling broad applicability across multiple squamous malignancies.<\/li>\n\n\n\n<li><strong>Indications<\/strong> \u2013 designed for treatment of <strong>squamous cell carcinomas<\/strong>, specifically <strong>squamous non\u2011small cell lung cancer (sq\u2011NSCLC)<\/strong> and <strong>head\u2011and\u2011neck squamous cell carcinoma (HNSCC)<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-development-milestones\">Development Milestones<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Date<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>FDA IND Approval<\/strong><\/td><td>March\u202f2025<\/td><td>Validated global safety and efficacy profile; opened U.S. clinical pathway.<\/td><\/tr><tr><td><strong>NMPA IND Approval<\/strong><\/td><td>October\u202f13\u202f2025<\/td><td>Enables launch of Phase\u202f1\/2 trials in China; expands patient access.<\/td><\/tr><tr><td><strong>Platform Validation<\/strong><\/td><td>2024\u20112025<\/td><td>Demonstrated robust immunogenicity against all five TAAs in pre\u2011clinical models.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-significance\">Strategic Significance<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011in\u2011Class Therapeutic Vaccine<\/strong> \u2013 EVM14 represents the first universal, off\u2011the\u2011shelf mRNA vaccine targeting multiple TAAs in squamous cancers.<\/li>\n\n\n\n<li><strong>Market Potential<\/strong> \u2013 With an estimated <strong>$20\u202fbillion+<\/strong> global market for squamous NSCLC and HNSCC, EVM14 could capture a significant share of unmet therapeutic needs.<\/li>\n\n\n\n<li><strong>Accelerated Pathway<\/strong> \u2013 Dual FDA and NMPA approvals accelerate the path toward global Phase\u202f3 studies, positioning Everest for a leadership role in the oncology vaccine arena.<\/li>\n<\/ul>\n\n\n\n<p><strong>About Everest Medicines<\/strong><br>Everest Medicines Limited is a Hong\u202fKong\u2011listed (HKG:\u202f1952) biotechnology company focused on the discovery, development, and commercialization of innovative mRNA therapeutics. The company\u2019s platform enables rapid, scalable vaccine development for cancer and infectious diseases.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Everest Medicines Limited (HKG: 1952) announced today that the National Medical Products Administration (NMPA) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43177,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,126,1164,12],"class_list":["post-43176","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-everest-medicines","tag-hkg-1952","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Everest Medicines Receives NMPA Approval for Universal Oncology Vaccine EVM14 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Everest Medicines Limited (HKG: 1952) announced today that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its universal, off\u2011the\u2011shelf therapeutic oncology vaccine EVM14 for Injection. The IND clearance follows the U.S. Food and Drug Administration (FDA) approval of the same clinical trial in March\u202f2025, positioning EVM14 for accelerated global development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43176\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Everest Medicines Receives NMPA Approval for Universal Oncology Vaccine EVM14\" \/>\n<meta property=\"og:description\" content=\"Everest Medicines Limited (HKG: 1952) announced today that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its universal, off\u2011the\u2011shelf therapeutic oncology vaccine EVM14 for Injection. The IND clearance follows the U.S. Food and Drug Administration (FDA) approval of the same clinical trial in March\u202f2025, positioning EVM14 for accelerated global development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43176\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-13T09:22:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-13T09:22:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1307.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43176#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43176\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Everest Medicines Receives NMPA Approval for Universal Oncology Vaccine EVM14\",\"datePublished\":\"2025-10-13T09:22:19+00:00\",\"dateModified\":\"2025-10-13T09:22:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43176\"},\"wordCount\":286,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43176#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1307.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Everest Medicines\",\"HKG: 1952\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43176#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43176\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43176\",\"name\":\"Everest Medicines Receives NMPA Approval for Universal Oncology Vaccine EVM14 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43176#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43176#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1307.webp\",\"datePublished\":\"2025-10-13T09:22:19+00:00\",\"dateModified\":\"2025-10-13T09:22:20+00:00\",\"description\":\"Everest Medicines Limited (HKG: 1952) announced today that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its universal, off\u2011the\u2011shelf therapeutic oncology vaccine EVM14 for Injection. The IND clearance follows the U.S. Food and Drug Administration (FDA) approval of the same clinical trial in March\u202f2025, positioning EVM14 for accelerated global development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43176#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43176\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43176#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1307.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1307.webp\",\"width\":1080,\"height\":608,\"caption\":\"Everest Medicines Receives NMPA Approval for Universal Oncology Vaccine EVM14\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43176#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Everest Medicines Receives NMPA Approval for Universal Oncology Vaccine EVM14\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Everest Medicines Receives NMPA Approval for Universal Oncology Vaccine EVM14 - Insight, China&#039;s Pharmaceutical Industry","description":"Everest Medicines Limited (HKG: 1952) announced today that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its universal, off\u2011the\u2011shelf therapeutic oncology vaccine EVM14 for Injection. The IND clearance follows the U.S. Food and Drug Administration (FDA) approval of the same clinical trial in March\u202f2025, positioning EVM14 for accelerated global development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43176","og_locale":"en_US","og_type":"article","og_title":"Everest Medicines Receives NMPA Approval for Universal Oncology Vaccine EVM14","og_description":"Everest Medicines Limited (HKG: 1952) announced today that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its universal, off\u2011the\u2011shelf therapeutic oncology vaccine EVM14 for Injection. The IND clearance follows the U.S. Food and Drug Administration (FDA) approval of the same clinical trial in March\u202f2025, positioning EVM14 for accelerated global development.","og_url":"https:\/\/flcube.com\/?p=43176","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-13T09:22:19+00:00","article_modified_time":"2025-10-13T09:22:20+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1307.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43176#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43176"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Everest Medicines Receives NMPA Approval for Universal Oncology Vaccine EVM14","datePublished":"2025-10-13T09:22:19+00:00","dateModified":"2025-10-13T09:22:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43176"},"wordCount":286,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43176#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1307.webp","keywords":["Clinical trial approval \/ initiation","Everest Medicines","HKG: 1952","Vaccine"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43176#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43176","url":"https:\/\/flcube.com\/?p=43176","name":"Everest Medicines Receives NMPA Approval for Universal Oncology Vaccine EVM14 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43176#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43176#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1307.webp","datePublished":"2025-10-13T09:22:19+00:00","dateModified":"2025-10-13T09:22:20+00:00","description":"Everest Medicines Limited (HKG: 1952) announced today that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its universal, off\u2011the\u2011shelf therapeutic oncology vaccine EVM14 for Injection. The IND clearance follows the U.S. Food and Drug Administration (FDA) approval of the same clinical trial in March\u202f2025, positioning EVM14 for accelerated global development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43176#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43176"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43176#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1307.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1307.webp","width":1080,"height":608,"caption":"Everest Medicines Receives NMPA Approval for Universal Oncology Vaccine EVM14"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43176#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Everest Medicines Receives NMPA Approval for Universal Oncology Vaccine EVM14"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1307.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43176","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43176"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43176\/revisions"}],"predecessor-version":[{"id":43178,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43176\/revisions\/43178"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43177"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43176"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43176"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43176"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}